Immuno-Oncology Strategic Industry Research Report 2023-2024 & 2030: Approval of Pembrolizumab (Keytruda) and Nivolumab (Opdivo), which Target PD-1 and PD-L1 Pathways have Set New Benchmarks
05. Dezember 2024 10:16 ET
|
Research and Markets
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Immuno-Oncology...
Global TCR Therapy Pipeline Landscape Opportunity Assessment 2021: Companies, Drugs, Therapeutics, Phases, Trends and Outlook
16. Dezember 2021 10:08 ET
|
Research and Markets
Dublin, Dec. 16, 2021 (GLOBE NEWSWIRE) -- The "TCR Therapy - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights...